{"entity":{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of balstilimab and cyclophosphamide in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","summary":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06782932 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 38 participants, started 2025-05-27 and due to reach its primary completion in 2028-12. Interventions recorded: AGEN2373; Balstilimab; Cyclophosphamide; GVAX; AGEN2373 (RP2D); Balstilimab; mKRASvax. Conditions listed: Pancreatic Cancer. Primary outcome: Dose Limiting Toxicities in Phase I participants; Number of participants experiencing Grade 3 or Higher study drug-related toxicities; Number of participants who form Intratumoral tertiary lymphoid structures (TLS). Pancreatic eligibility wording from the registry: \"* Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06782932","url":"https://clinicaltrials.gov/study/NCT06782932"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","shared-antigen-vaccine"],"targets":[],"drugs":["balstilimab","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06782932","phase":"1/2","setting":"A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06782932/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"drug":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}